Literature DB >> 11844568

The dorsomedial shell of the nucleus accumbens facilitates cocaine-induced locomotor activity during the induction of behavioral sensitization.

M S Todtenkopf1, T Carreiras, R H Melloni, J R Stellar.   

Abstract

The mesolimbic dopamine system has been intensely studied as the neural circuit mediating the locomotor response to psychostimulants and behavioral sensitization. In particular, the dopaminergic innervation of the nucleus accumbens has been implicated as a site responsible for the manifestations of behavioral sensitization. Previous studies have demonstrated an augmented release of dopamine in the nucleus accumbens upon a systemic injection of a psychostimulant. In addition, alterations in the dopaminergic innervation patterns in this brain region have been demonstrated in animals that received repeated injections of cocaine. Furthermore, lesions of projection sites that have terminations in the nucleus accumbens have demonstrated alterations in psychostimulant induced locomotion, both acutely, as well as in sensitization paradigms. Since dopamine in the nucleus accumbens is believed to regulate several excitatory amino acid inputs, the present study examined the effects of a localized electrolytic lesion in the dorsomedial shell of the nucleus accumbens in order to better understand the functional role this brain region has in behavioral sensitization. All animals received bi-daily injections of 15 mg/kg i.p. cocaine. Only those demonstrating behavioral sensitization after a subsequent challenge dose were included in the analysis. Following acute exposure to cocaine, lesioned animals did not show any difference in their locomotor response when compared with sham controls. However, after repeated exposure to cocaine, sensitized animals demonstrated a significant attenuation in locomotor behavior when compared with sensitized sham controls. This decrease in horizontal locomotion persisted 2 days into withdrawal, yet dissipated in the sensitized animals that were challenged 2 weeks following their last injection. The data presented here demonstrate that the dorsomedial shell of the nucleus accumbens plays an important role in the initial stages of behavioral sensitization to cocaine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844568     DOI: 10.1016/s0166-4328(01)00352-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  5 in total

1.  A silent synapse-based mechanism for cocaine-induced locomotor sensitization.

Authors:  Travis E Brown; Brian R Lee; Ping Mu; Deveroux Ferguson; David Dietz; Yoshinori N Ohnishi; Ying Lin; Anna Suska; Masago Ishikawa; Yanhua H Huang; Haowei Shen; Peter W Kalivas; Barbara A Sorg; R Suzanne Zukin; Eric J Nestler; Yan Dong; Oliver M Schlüter
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Individual differences in the attribution of incentive salience to a reward-related cue: influence on cocaine sensitization.

Authors:  Shelly B Flagel; Stanley J Watson; Huda Akil; Terry E Robinson
Journal:  Behav Brain Res       Date:  2007-07-21       Impact factor: 3.332

3.  Nucleus accumbens lesions modulate the effects of methylphenidate.

Authors:  Adam Podet; Min J Lee; Alan C Swann; Nachum Dafny
Journal:  Brain Res Bull       Date:  2010-05-12       Impact factor: 4.077

4.  Dopamine transporter inhibition is necessary for cocaine-induced increases in dendritic spine density in the nucleus accumbens.

Authors:  Bradley J Martin; Bartholomew J Naughton; Keerthi Thirtamara-Rajamani; Daniel J Yoon; Dawn D Han; A Courtney Devries; Howard H Gu
Journal:  Synapse       Date:  2010-11-09       Impact factor: 2.562

5.  Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice.

Authors:  Adele Stewart; Gwynne L Davis; Paul J Gresch; Rania M Katamish; Rodeania Peart; Maximilian J Rabil; Raajaram Gowrishankar; F Ivy Carroll; Maureen K Hahn; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2018-12-21       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.